Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > China

<< Previous

Bullboard Posts

Next >>

Post by qwerty22on Oct 24, 2021 5:01pm

319 Views

Post# 34042427

China

https://www.pharmadj.com/en/cms/detail.htm?item.id=1609c6932bf711ecbee6fa163e42049a

I thought this was an interesting article. The tendency in China is to focus on drugs with proven MOAs which has led to developers all going after the same target. Chinese regulators have shook this up with their latest guidance. May make developers look to drugs with new innovative MOAs. Higher risk but better regulatory path to approval.

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features